NASDAQ:HROW

Harrow Health Stock Forecast, Price & News

$10.50
+0.63 (+6.38 %)
(As of 06/24/2021 11:04 AM ET)
Add
Compare
Today's Range
$10.27
$10.69
50-Day Range
$7.30
$11.07
52-Week Range
$4.65
$11.24
Volume3,387 shs
Average Volume245,193 shs
Market Capitalization$279.11 million
P/E Ratio28.38
Dividend YieldN/A
Beta0.91
30 days | 90 days | 365 days | Advanced Chart
Receive HROW News and Ratings via Email

Sign-up to receive the latest news and ratings for Harrow Health and its competitors with MarketBeat's FREE daily newsletter.


Harrow Health logo

About Harrow Health

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and Visionology, a membership-based online eye health and medication platform. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in San Diego, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.95 out of 5 stars

Medical Sector

101st out of 2,105 stocks

Pharmaceutical Preparations Industry

43rd out of 832 stocks

Analyst Opinion: 3.5Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 2.5 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Harrow Health (NASDAQ:HROW) Frequently Asked Questions

Is Harrow Health a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harrow Health in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Harrow Health stock.
View analyst ratings for Harrow Health
or view top-rated stocks.

What stocks does MarketBeat like better than Harrow Health?

Wall Street analysts have given Harrow Health a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Harrow Health wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Harrow Health's next earnings date?

Harrow Health is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Harrow Health
.

How were Harrow Health's earnings last quarter?

Harrow Health, Inc. (NASDAQ:HROW) announced its quarterly earnings results on Tuesday, May, 11th. The company reported $0.01 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.04 by $0.03. The firm had revenue of $15.44 million for the quarter, compared to analysts' expectations of $15.01 million. Harrow Health had a trailing twelve-month return on equity of 9.38% and a net margin of 18.60%.
View Harrow Health's earnings history
.

How has Harrow Health's stock been impacted by Coronavirus (COVID-19)?

Harrow Health's stock was trading at $4.76 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, HROW shares have increased by 120.6% and is now trading at $10.50.
View which stocks have been most impacted by COVID-19
.

What guidance has Harrow Health issued on next quarter's earnings?

Harrow Health issued an update on its first quarter 2021 earnings guidance on Tuesday, May, 4th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $14.90 million-$15.50 million, compared to the consensus revenue estimate of $13.66 million.

What price target have analysts set for HROW?

1 Wall Street analysts have issued 12-month price objectives for Harrow Health's shares. Their forecasts range from $15.00 to $15.00. On average, they expect Harrow Health's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 42.9% from the stock's current price.
View analysts' price targets for Harrow Health
or view top-rated stocks among Wall Street analysts.

Who are Harrow Health's key executives?

Harrow Health's management team includes the following people:
  • Mr. Mark L. Baum, CEO & Director (Age 48, Pay $838.3k)
  • Mr. Andrew R. Boll C.F.A., C.M.A., CFA, CMA, CFO & Corp. Sec. (Age 39, Pay $574.96k)
  • Mr. John P. Saharek, Pres of ImprimisRx (Age 61, Pay $446.14k)
  • Mr. David Moufarrège, VP of Technology
  • Dr. Dennis E Saadeh Pharm.D., Chief of Formulation Strategy
  • Dr. Larry M. Dillaha, Chief Medical Officer
  • Mr. Andrew Livingston, Chief Innovation Officer

Who are some of Harrow Health's key competitors?

What other stocks do shareholders of Harrow Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harrow Health investors own include NVIDIA (NVDA), Aldeyra Therapeutics (ALDX), OPKO Health (OPK), QUALCOMM (QCOM), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), VBI Vaccines (VBIV), Exelixis (EXEL) and Mustang Bio (MBIO).

What is Harrow Health's stock symbol?

Harrow Health trades on the NASDAQ under the ticker symbol "HROW."

Who are Harrow Health's major shareholders?

Harrow Health's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (6.08%), Renaissance Technologies LLC (6.02%), Ophir Asset Management Pty Ltd (4.84%), Uniplan Investment Counsel Inc. (1.93%), Acadian Asset Management LLC (1.63%) and Geode Capital Management LLC (1.44%). Company insiders that own Harrow Health stock include Opaleye Management Inc, Richard L Md Lindstrom and Robert J Kammer.
View institutional ownership trends for Harrow Health
.

Which major investors are selling Harrow Health stock?

HROW stock was sold by a variety of institutional investors in the last quarter, including Diametric Capital LP, Millennium Management LLC, Northern Trust Corp, Zebra Capital Management LLC, UBS Group AG, Trexquant Investment LP, Arrowstreet Capital Limited Partnership, and Corrado Advisors LLC.
View insider buying and selling activity for Harrow Health
or view top insider-selling stocks.

Which major investors are buying Harrow Health stock?

HROW stock was acquired by a variety of institutional investors in the last quarter, including Ophir Asset Management Pty Ltd, Morgan Stanley, Wedge Capital Management L L P NC, Boston Partners, Renaissance Technologies LLC, Dimensional Fund Advisors LP, BlackRock Inc., and Geode Capital Management LLC.
View insider buying and selling activity for Harrow Health
or or view top insider-buying stocks.

How do I buy shares of Harrow Health?

Shares of HROW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Harrow Health's stock price today?

One share of HROW stock can currently be purchased for approximately $10.50.

How much money does Harrow Health make?

Harrow Health has a market capitalization of $279.11 million and generates $48.87 million in revenue each year. The company earns $-3,360,000.00 in net income (profit) each year or ($0.05) on an earnings per share basis.

How many employees does Harrow Health have?

Harrow Health employs 125 workers across the globe.

What is Harrow Health's official website?

The official website for Harrow Health is www.harrowinc.com.

Where are Harrow Health's headquarters?

Harrow Health is headquartered at 102 Woodmont Blvd. Suite 610, Nashville TN, 37205.

How can I contact Harrow Health?

Harrow Health's mailing address is 102 Woodmont Blvd. Suite 610, Nashville TN, 37205. The company can be reached via phone at (615) 733-4730 or via email at [email protected]


This page was last updated on 6/24/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.